Journal Article

Susceptibility of porcine cytomegalovirus to antiviral drugs

Jacqueline F. L. Fryer, Paul D. Griffiths, Vincent C. Emery and Duncan A. Clark

in Journal of Antimicrobial Chemotherapy

Published on behalf of British Society for Antimicrobial Chemotherapy

Volume 53, issue 6, pages 975-980
Published in print June 2004 | ISSN: 0305-7453
Published online June 2004 | e-ISSN: 1460-2091 | DOI:
Susceptibility of porcine cytomegalovirus to antiviral drugs

Show Summary Details


Objectives: Re-activation of porcine cytomegalovirus (PCMV) in the xenograft has been reported in pig-to-baboon models of xenotransplantation and is associated with invasive disease and consumptive coagulopathy. If xenotransplantation of porcine organs into human recipients is to proceed, donor organs will have to be free from a wide range of infectious agents including PCMV. However, it is prudent to characterize the antiviral susceptibility of this virus. We therefore investigated the effect of selected antiviral agents, currently licensed for the treatment of human herpesvirus infections, on PCMV replication.

Methods: Antiviral susceptibility was determined using real-time PCR and indirect immunofluorescence measurements in a porcine fallopian tube cell line infected with PCMV.

Results: PCMV replication was significantly inhibited by ganciclovir and cidofovir (both EC50 < 1 mg/L) and to a lesser extent by foscarnet (EC50 within range 25–50 mg/L) and aciclovir (EC50 > 25 mg/L).

Conclusions: These results show that, if it proves necessary, ganciclovir and cidofovir should be considered as first-line drugs to treat PCMV infections in xenograft recipients.

Keywords: Keywords: xenotransplantation, ganciclovir, cidofovir

Journal Article.  3438 words.  Illustrated.

Subjects: Medical Oncology ; Critical Care

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.